[1] |
CAO Fei, YU Wenhao, TANG Xiaonan, MA Zidong, CHANG Tingmin, GONG Yabin, LIAO Mingjuan, KANG Xiaohong.
Mechanism of LINC01410 promoting proliferation and migration in esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(8): 753-762.
|
[2] |
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan.
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(7): 669-679.
|
[3] |
SHEN Jie, FENG Xiaoshuang, WEN Hao, ZHOU Changming, MO Miao, WANG Zezhou, YUAN Jing, WU Xiaohua, ZHENG Ying.
Metastasis patterns and survival analysis of 572 patients with metastatic cervical cancer: a hospital-based real world study
[J]. China Oncology, 2024, 34(4): 361-367.
|
[4] |
SHEN Jie, WANG Jiangli, WANG Zezhou, MO Miao, ZHOU Changming, YUAN Jing, XU Dazhi, ZHENG Ying.
Survival analysis of 6 737 surgically resected gastric cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2024, 34(3): 268-277.
|
[5] |
LI Jing, ZHENG Lei, GAO Yu.
Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer
[J]. China Oncology, 2024, 34(3): 286-292.
|
[6] |
CHEN Luyan, WANG Lixue, FU Peifen.
The value of surgery in the patients with de novo stage Ⅳ breast cancer
[J]. China Oncology, 2023, 33(5): 431-436.
|
[7] |
CHEN Lijun, WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan.
Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma
[J]. China Oncology, 2023, 33(5): 469-477.
|
[8] |
LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda.
Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis
[J]. China Oncology, 2022, 32(8): 705-711.
|
[9] |
HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu.
Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(7): 624-634.
|
[10] |
MA Xiao, XIANG Jiaqing, MA Longfei.
Surgical treatment of esophagotracheal fistula caused by neoadjuvant chemotherapy for locally advanced esophageal cancer: a case report
[J]. China Oncology, 2022, 32(6): 542-544.
|
[11] |
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun.
Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients
[J]. China Oncology, 2022, 32(4): 357-362.
|
[12] |
DUAN Yuqing, XIA Ning, JIA Yunlong, ZHENG Wenya, LIU Lihua.
SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing
[J]. China Oncology, 2022, 32(3): 191-199.
|
[13] |
WANG Zimao, CAO Yuan, WANG Qiying.
Construction and validation of the survival prediction model for patients with cutaneous spindle cell melanoma
[J]. China Oncology, 2022, 32(3): 234-242.
|
[14] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[15] |
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin.
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
[J]. China Oncology, 2022, 32(1): 13-23.
|